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p53 and p73 proteins activate similar target genes and
induce apoptosis and cell cycle arrest. However, p53, but
not p73 is considered a tumour-suppressor gene. Unlike
p53, p73 deficiency in mice does not lead to a cancer-
prone phenotype, and p73 gene is not mutated in human
cancers, including hepatocellular carcinoma. Here we
report that normal liver cells express only DN-p73
transcript forms giving rise to the synthesis of N-
terminally truncated, transcriptionally inactive and
dominant negative p73 proteins. In contrast, most
hepatocellular carcinoma cells express TA-p73 transcript
forms encoding full-length and transcriptionally active
p73 proteins, in addition to DN-p73. We also show that
together with the acquired expression of TA-p73, the
‘retinoblastoma pathway’ is inactivated, and E2F1-target
genes including cyclin E and p14ARF are activated in
hepatocellular carcinoma. However, there was no full
correlation between ‘retinoblastoma pathway’ inactiva-
tion and TA-p73 expression. Most TA-p73-expressing
hepatocellular carcinoma cells have also lost p53 function
either by lack of expression or missense mutations. The
p73 gene, encoding only DN-p73 protein, may function
as a tumour promoter rather than a tumour suppressor in
liver tissue. This may be one reason why p73 is not a
mutation target in hepatocellular carcinoma. Oncogene
(2001) 20, 5111 – 5117.
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Introduction
The p53 and its newly discovered homologues,
namely p73 and p63 form a family of genes that
activate similar target genes, and induce apoptosis
and cell cycle arrest (Marin and Kaelin, 2000;
Lohrum and Vousden, 2000). However, p53, but
not the other family members, is considered a
tumour-suppressor gene. For example, unlike p53,
p73 deficiency in mice does not lead to a cancer-
prone phenotype (Yang et al., 2000), and p73 gene is
not mutated in human tumours, including hepatocel-
lular carcinoma (HCC) (Marin and Kaelin, 2000;
Mihara et al., 1999). Presently, the reasons for this
discrepancy are not known. One of the major
dierences between p53 and the two other family
members is the ability of p63 and p73 genes to
encode multiple transcript isoforms (Marin and
Kaelin, 2000; Lohrum and Vousden, 2000). Dierent
p63 and p73 C-termini are generated as a result of
alternative splicing between exons 10 – 15 and 10 – 14,
respectively (Marin and Kaelin, 2000). In addition,
p63 utilizes a cryptic promoter located in intron 3 to
generate additional transcripts called DN-p63 iso-
forms (Yang et al., 1998).
Our knowledge on truncated DN-p73 isoforms is
scarce, but DN-p73 transcripts lacking transactivation
domain were proposed to be predominant p73 gene
products in some mouse tissues (Yang et al., 2000).
Pozniak et al. (2000) have recently demonstrated that
p73 is primarily present in developing neurons as a
truncated DN-p73 isoform in mouse. Like the tran-
scripts encoding DN-p63 (Yang et al., 1998), murine
DN-p73 messages were derived from an alternative
promoter located in intron 3, and DN-p73 failed to
activate transcription from a p53-reporter gene, but
suppressed the transactivation activity of both TA-
p73a and wild-type p53 (Yang et al., 2000; Pozniak et
al., 2000). On the other hand, most, if not all reported
studies on the expression of p73 in dierent cancers did
not distinguish between DN-p73 and TA-p73 isoforms
(reviewed in Marin and Kaelin, 2000; Lohrum and
Vousden, 2000).
With regard to p73 implications in liver malig-
nancy, Tannapfel et al. (1999a,b) have reported that
both p73 transcripts and protein were undetectable in
most normal liver cells, but p73 protein was over-
expressed in a subset of HCCs, and could serve as an
indicator of poor prognosis (Tannapfel et al., 1999b).
On the other hand, Mihara et al. (1999) reported the
absence of mutation, as well as absence of over-
expression of p73 gene in HCC. These observations
were in apparent contradiction and they did not
provide evidence about the mechanisms of p73
involvement in liver malignancy. These reports,
together with the identification DN-p73 in some
mouse tissues (Yang et al., 2000; Pozniak et al.,
2000), led us to test whether p73 expression in
normal liver and HCC diers in terms of DN-p73
and TA-p73 isoforms. We also compared p73
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expression in HCC cells with the status of ‘retino-
blastoma pathway’ and p53.
Results
By comparison of murine p73 cDNA sequences with
that of human p73 gene, we developed assays for
identification and detection of DN-p73 and TA-p73
transcript isoforms (Figure 1a). Initial RT –PCR
assays and nucleic acid sequencing identified DN-p73
isoform in SNU 398 HCC cell line (Figure 1b). The
DN-p73 was also detected uniformly in mouse, rat
(data not shown) and human liver tissues, as well as
HCC cell lines (Figure 1c). In contrast, TA-p73 was
not detectable in normal liver, but it was present in 14/
15 (93%) of HCC cell lines. However, TA-p73 bands
displayed various intensities. They were at the limit of
detection in cDNAs from SNU 182 and SNU 423 cell
lines, and there was no detectable TA-p73 expression in
Mahlavu cell line (Figure 1c). p73 transcripts also dier
in their 3’ regions because of alternative splicing
between exons 10 to 14, giving rise to a, b, g, d, e
and f isoforms (Zaika et al., 1999). p73 transcripts
expressed in normal liver and HCC cell lines were
mainly a, b and f isoforms (data not shown). To
confirm the expression of DN-p73 and TA-p73, we
tested the presence of these protein isoforms in SNU
398 as compared to COS7 (Figure 1d), using ER 13
monoclonal antibody against amino acids 495 – 636 of
p73-a (Oncogene Research Products, MA, USA). This
antibody was shown to react with the a, but not b
isoform of p73 protein (Marin et al., 1998). As shown
in Figure 1d, ER13 antibody reacted with full-length
p73-a (i.e. TA-p73-a) in COS7 cell line which was used
as a positive control (Marin et al., 1998). SNU 398 cell
line expressed TA-p73-a similar to COS7, but also a
shorter polypeptide with an apparent molecular weight
of 62 kD. This polypeptide can not be p73-b because
of ER 13 specificity. Its apparent molecular weight
correlates with that of mouse DN-p73-a described by
Pozniak et al. (2000). Since, SNU 398 express both
TA-p73 and DN-p73 transcripts (Figure 1c), the
presence of both TA-p73 and DN-p73 proteins in this
cell line is expected.
Next, p73 expression was studied in primary HCC
tumours. As shown in Figure 1e, all tumours, as well
as non tumour liver samples expressed DN-p73
isoform. In addition, two of seven (29%) HCC tumour
samples expressed TA-p73 isoform. An additional
tumour (T1) displayed a weakly positive TA-p73 band.
There was no detectable TA-p73 in the remaining T3,
T4, T6 and T7 tumours, as well as in non tumour liver
NT1. Thus, acquired expression of TA-p73 in HCC
was demonstrated in both primary HCC tumours and
HCC-derived cell lines. However, the presence of TA-
p73 was more frequent in cell lines than primary
tumours. The TA-p73 transcripts shown in Figure 1
were tested with a primer pair located on exons 3 and
4, respectively. It has recently been described that, in
some breast carcinoma cell lines overexpressing TA-
p73, a transactivation-deficient splice variant lacking
exon 2 (p73Dexon2) is also detected (Fillippovich et al.,
2001). Since our TA-p73 transcript test system would
not distinguish between TA-p73 and p73Dexon2, we
performed additional RT –PCR experiments. Using a
forward primer located on exon 1 together with a
reverse primer located on exon 4 (Fillippovich et al.,
2001), we detected mainly TA-p73 transcripts in both
primary HCC and cell lines (data not shown). This
confirms that TA-p73 forms described in Figure 1 are
indeed full-length forms, even though one can not rule
out a weak expression of p73Dexon2 form in some cell
lines.
Induced expression of TA-p73 in some HCCs
suggested that its expression is acquired during
malignant transformation of hepatocytes. Recently,
E2F1 transcription factor has been shown to activate
p73 transcription through E2F1-binding motifs around
non-coding exon 1 of p73 gene (Stiewe and Putzer
2000; Lissy et al., 2000; Irwin et al., 2000; Zaika et al.,
2001). E2F1-responsive p73 gene products have been
identified as full-length p73a and p73b proteins (Stiewe
and Putzer, 2000; Lissy et al., 2000; Irwin et al., 2000)
that can be encoded by TA-p73, but not DN-p73
transcript isoforms (Figure 1a). Thus, we hypothesized
that the selective induction of TA-p73 expression in
HCC tumours is due to E2F1 activation. Therefore, we
also tested the expression of E2F1 target genes p14ARF
and CCNE1 encoding cyclin E (Dyson, 1998). As
shown in Figure 1e, the expression of cyclin E was
induced in three tumours (T1, T2, T5), as compared to
non tumour liver tissue NT1. The expression of p14ARF
was also induced in two tumours (T1 and T2). It was
also noteworthy that in TA-p73-positive T2 and T5
tumours, cyclin E expression was also induced, but
only T2 showed p14ARF induction. Thus, three E2F1
target genes (i.e. p73, Cyclin E and p14ARF) were
induced in some HCC tumours. However, there was
no full correlation between their expression patterns in
dierent tumours. This could be due to the quality of
RNA extracted from these archival tumour tissues.
(We were not able to test additional samples, because
HCC is a rarely operated tumour). Alternatively, the
expression of these E2F1 target genes in HCC may be
under the influence of additional factors.
As the activity of E2F1 is controlled by the protein
product of retinoblastoma (RB1) gene (pRb) (Dyson,
1998), we studied whether the induction of TA-p73
expression is related to the inactivation of ‘retinoblas-
toma pathway’ in HCC cells. The ‘retinoblastoma
pathway’ in cancer cells is altered mainly by inactiva-
tion of either RB1 or p16INK4a gene (Dyson, 1998). In
HCC, RB1 mutations are rare, but allelic loss and
decreased pRb levels occur frequently (reviewed in
Ozturk, 1999), which may be due to overexpression of
gankyrin that reduces the stability of pRb, and releases
‘free E2F1’ (Higashitsuji et al., 2000). Loss of p16INK4a
expression by gene deletion or promoter methylation is
also common in HCC (see Ozturk, 1999; Baek et al.,
2000). Therefore, we compared the expression of TA-
p73 with the expression of pRb protein and p16INK4a
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Figure 1 Identification of TA-p73 and DN-p73 transcripts and their expression in normal liver, HCC cell lines and primary HCC
tumours, as compared to E2F1 target genes cyclin E and p14ARF. (a) Exon-intron structure of 5’ coding region of human p73 gene
showing the transcription start sites and splicing events leading to TA-p73 and DN-p73 isoforms. Initiation of transcription in exon
1 produces the TA-isoforms, containing the transactivation (TA) domain (previously called p73), while initiation in exon 3’ gives rise
to the DN-isoforms without the TA domain. The putative transcriptional start site and exon 3’ for DN-p73 were identified by in
silico analysis of human p73 gene, as compared to mouse DN-p73 transcript sequence. Primers TAF and DNF indicate the positions
of isoform-specific forward primers used to identify respectively TA-p73 and DN-p73 transcripts, in combination with Primer R
common to both isoforms. (b) Partial nucleotide and amino acid sequences of human TA-p73 and DN-p73 transcript isoforms as
compared to mouse DN-p73 isoform. Data for human DN-p73 was obtained from direct sequencing of a 186 bp RT–PCR product
obtained from SNU 398 HCC cell line, using DNF and R primer pair. (c) As compared to normal liver (NL), the expression of TA-
p73, but not DN-p73 is induced strongly in 14 out of 15 (93%) HCC cell lines. TA-p73 and DN-p73 isoforms were tested as
described in a. GAPDH was used as a control for equal template loading in PCR. Neg; negative control. (d) Western blot analysis
of p73 protein in SNU 398 and COS7 reveals the presence of a *62 kD polypeptide (presumably DN-p73 according to Pozniak et
al., 2000) in SNU 398, in addition to TA-p73 protein present in both cell lines. Five-hundred mg total protein was analysed with
anti-p73 ER13 monoclonal antibody which recognizes p73-a, but not p73-b isoforms (Marin et al., 1998). (e) Expression of TA-p73,
DN-p73, cyclin E and p14ARF transcripts in primary HCC tumours. RT–PCR analysis using oligonucleotide primers shown in a,
reveals the expression of DN-p73 in all samples tested. TA-p73 is easily detected in two out of seven tumours (T2, T5), T1 shows
only weak expression, non tumour liver NT1 (counterpart of T1) is negative. Similarly, cyclin E expression is also induced in T1, T2,
and T5, but p14ARF transcripts are induced only in T1 and T2. GAPDH was used as a control for equal template loading in PCR.
Neg; negative control
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transcripts in HCC cell lines. The expression of either
pRb or p16INK4a was lost in six cell lines, and
significantly decreased in five others. Thus, ‘retinoblas-
toma pathway’ appeared to be inactivated in at least 11
out of 15 (73%) cell lines (Figure 2a). Indeed, this
inactivation has previously been reported for eight of
these cell lines (Morel et al., 2000; Baek et al., 2000;
Puisieux et al., 1993; Suh et al., 2000). In support of
this conclusion, the expression of E2F1 target genes
cyclin E and p14ARF were also induced in all cell lines,
except three for p14ARF (Figure 2b), due to CDKN2A
gene deletion in SNU 387 and SNU 449 (Baek et al.,
2000), and probably in SK-Hep1. These studies showed
that both the inactivation of ‘retinoblastoma pathway’
and the induction of TA-p73 expression are relatively
common events in HCC cell lines. However, our
observations do not allow establishing a direct
correlation between these two events. Additional
studies are needed to address this issue.
The overexpression of TA-p73 is not compatible
with cellular growth (Marin and Kaelin, 2000; Fang et
al., 1999), but HCC cells can apparently tolerate TA-
p73 expression (Figure 1c). The DN-p73, co-expressed
in these cells, is known to suppress both TA-p73 and
p53 activities (Yang et al., 2000; Pozniak et al., 2000).
In addition, some tumour-derived p53 mutant proteins
were shown to bind and inactivate TA-p73 protein
(Marin and Kaelin, 2000; Di Como et al., 1999; Strano
Figure 2 Comparative analysis of the status of retinoblastoma pathway (pRb and p16INK4a), E2F1 target (cyclin E and p14ARF)
and p53 genes in HCC cell lines. (a) Either pRb or p16INK4a expression is totally lost (Hep3B, SNU 387, SNU 449, Hep3B-TR,
Hep40, SK-Hep1), or significantly decreased (SNU 398, SNU 423, SNU 475, FOCUS, PLC/PRF/5) in 11 out of 15 (73%) cell lines
tested. Western blot analysis using antibody IF8 reveals that pRb protein is not detectable in HepB3, Hep3B-TR and Hep40, or
weakly positive in SNU 423, SNU 449 and FOCUS. The asterix (*) denotes a non-pRb cross-reactive antigen (Morel et al., 2000),
serving as a loading control for Western blot assay. RT–PCR analysis shows that p16INK4a is not detectable in SNU 387, SNU 449
and SK-Hep1, or weakly positive in SNU 398, SNU 423, SNU 475 and PLC/PRF/5. See Figure 1c for template loading control
using GAPDH. Negative control for p16INK4a RT–PCR is not shown. (b) The expression of E2F1 target cyclin E and p14ARF genes
is induced in HCC cell lines. RT–PCR analysis of cyclin E transcripts reveals that their expression is uniformly induced in all cell
lines tested, as compared to normal liver (NL). The induction of p14ARF expression is detectable in all but three cell lines. The lack
of expression in SNU 449 and SNU 387 (see Baek et al., 2000), and probably SK-Hep1 (notice the lack of both p16INK4a and
p14ARF expression) is due to CDKN2A gene deletion. See Figure 1c for the use of GAPDH as template loading control. Negative
control is not shown. (c) Western blot assay for p53 shows no expression in FOCUS, SNU 387, SNU 398, Hep3B, Hep3B-TR, and
high levels in Hep40, Mahlavu, PLC/PRF/5, SNU 423, SNU 449, Huh7, SNU 475 cell lines. Mahlavu and PLC/PRF/5 display
Arg249Ser, and Huh7 Tyr220Cys mutations. HepG2 and SK-Hep1 express wild-type p53 (Puisieux et al., 1993; Hsu et al., 1993).
pRb Western blot data was used as a loading control (as in a)
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et al., 2000; Marin et al., 2000; Gaiddon et al., 2001).
Therefore, we tested whether there was a correlation
between TA-p73 expression and p53 gene status in
HCC cells. As shown in Figure 2c, p53 protein was
either lost or mutant in at least eight out of 15 (53%)
cell lines tested.
Discussion
Our observations demonstrate that p73 gene in normal
liver cells encodes only truncated DN-p73 transcript
isoform. In mouse, this isoform was shown to code for
an inactive p73 protein, acting as a dominant negative
form on the activities of full-length TA-p73 as well as
wild-type p53 proteins (Yang et al., 2000; Pozniak et
al., 2000). The dominant expression of DN-p73
transcript isoform was demonstrated in normal liver
tissues from human, mouse as well as rat organisms
(see Figure 1c,e for human liver, other data not
shown). In contrast, p73 gene encodes both TA-p73
and DN-p73 isoforms in most HCC cell lines and some
primary tumours. The acquired expression of TA-p73
in HCC cells appears to be transformation-related
rather than proliferation-related, since Mahlavu cells
did not express detectable TA-p73 transcripts, while
expressing DN-p73 isoform (Figure 1c). We also
detected DN-p73, but not TA-p73 transcripts in
proliferating normal human fibroblast cell line MRC5
(data not shown).
Separate analysis of DN-p73 and TA-p73 tran-
scripts in liver and HCC has not been reported yet.
However, Tannapfel et al. (1999a) reported the
absence of p73 expression in normal hepatocytes,
using an antibody directed against amino acid
residues encoded by exon 3 of p73, which is absent
in DN-p73, but present in TA-p73 transcripts (see
Figure 1b). Studies with this antibody (together with
another anti-p73 antibody directed against a region
common to both TA-p73 and DN-p73 proteins) also
demonstrated that the p73 protein was negative in
non tumour liver tissues, but positive in 32% of
HCCs (Tannapfel et al., 1999b). Based on observa-
tions described here, it now appears that p73 detected
in these HCCs is the TA-p73 form, although this
requires a separate confirmation analysis with the
TA-p73-specific antibody alone.
The induction of TA-p73 and the ‘retinoblastoma
pathway’ inactivation was common in HCC cell lines
(Table 1). However, comparative studies did not allow
us to establish a link between the induction of TA-p73
expression and the inactivation of ‘retinoblastoma
pathway’. For example, the expression of E2F1-target
genes was also induced in cell lines with apparently
normal pRb and p16INK4a expression. Nevertheless, our
results indicate that ‘retinoblastoma pathway’ inactiva-
tion is common in HCC cell lines and it is
accompanied by an induction of E2F1 target genes
(i.e. p73, cyclin E and p14ARF) in most HCCs. This may
suggest that the acquired expression of TA-p73 in some
HCC cell lines is due to the inactivation of ‘retino-
blastoma pathway’. However, this remains to be
demonstrated with further studies.
The expression of DN-p73 in normal liver, and the
acquired expression of TA-p73 in HCC reveal new
implications for p73 in tumour biology. The p73 gene,
encoding only DN-p73 transcripts in normal liver, may
function as a tumour promoter rather than a tumour
suppressor in this tissue, by interfering with wild-type
p53 function (Yang et al., 2000; Pozniak et al., 2000).
This could explain why p73 is not mutated in HCC
(Mihara et al., 1999). However, p53 gene is frequently
mutated in HCC (Ozturk, 1999), as also demonstrated
here in HCC-derived cell lines (Figure 2c). Thus, DN-
p73 protein may not completely neutralize wild-type
p53 activity. Alternatively, the induction of TA-p73
transcription in tumour cells may redirect DN-p73
protein from wild-type p53 to newly expressed TA-p73
proteins.
On the other hand, the expression of TA-p73
transcripts in HCC cells is puzzling, based on the fact
that TA-p73 overexpression is known to induce growth
arrest and apoptosis (Marin and Kaelin, 2000; Lohrum
and Vousden, 2000). Therefore, HCC cells expressing
TA-p73 need to equip themselves with mechanism(s) to
tolerate TA-p73 protein expression. In addition to a
possible role of DN-p73 protein for TA-p73 inactiva-
tion (Yang et al., 2000; Pozniak et al., 2000), mutant
p53 proteins may also inactivate TA-p73, as reported
previously (Di Como et al., 1999; Strano et al., 2000;
Marin et al., 2000; Gaiddon et al., 2001). Accordingly,
several HCC cell lines reported here (Mahlavu, PLC/
PRF/5, Huh7 etc.) express mutant p53 proteins that
may inactivate TA-p73 protein. However, some other
cell lines (FOCUS, Hep3B, SNU 387, SNU 398 etc.)
have lost p53 expression. In this later group of cell
lines, the tolerance of TA-p73 expression may require
mutant p53-independent mechanisms. One additional
hypothesis is that TA-p73 protein levels and/or its
growth suppressive activities are regulated by post-
translational mechanisms, independent of both DN-p73
and mutant p53. For example, endogenous p73 protein
in a tumour cell line was shown to be stabilized by
cisplatin and by c-Abl kinase, with no change in p73
transcript levels (Gong et al., 1999). Moreover, the
apoptosis-inducing function of p73 was demonstrated
to be dependent to or enhanced by the c-Abl kinase in
dierent cell types (Yuan et al., 1999; Agami et al.,
1999; Gong et al., 1999). Thus, some HCC cell lines
may tolerate TA-p73 expression, if, for example, they
are deficient in c-Abl kinase activity.
Materials and methods
Tissues and cell lines
Normal liver tissues from Balb/c mice and Sprague-Dawley
rats were obtained after ether anaesthesia. Normal human
liver tissue was obtained from discarded surgical material
from a patient operated for hepatic hydatid cyst. Primary
HCC tumours and non tumour liver were freshly frozen
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archival materials. Fifteen human hepatoma-derived cell lines
(14 HCC and one hepatoblastoma), MRC5 and COS7 were
grown in culture as described (Morel et al., 2000). Most cell
lines were from ATCC, the others have been previously
described (Morel et al., 2000; Baek et al., 2000; Puisieux et
al., 1993; Bouzahzah et al., 1995).
RNA and cDNA preparations
Total RNA from cell lines and tissues was extracted using
NucleoSpin RNA II Kit (MN Macherey-Nagel, Duren,
Germany) and TriPure reagent (Boehringer Mannheim,
Indianapolis, IN, USA), respectively. The cDNAs were
prepared from total RNA (5 mg) using RevertAid First
Strand cDNA Synthesis Kit (MBI-Fermentas, Vilnius,
Lithuania).
Transcript analysis by RT–PCR
For the identification of TA-p73 and DN-p73 forms, we used
the available human p73 genomic sequence and mouse DN-
p73 cDNA sequence data and designed two forward and one
reverse (Primer R; 5’-GCGACATGGTGTCGAAGGTG-
GAGC-3’) primers to specifically amplify these forms from
human, mouse and rat tissues. These sequences were selected
on the basis of highest homology between mouse and human
DNA sequences (maximum one mismatch, data not shown).
The forward primers TAF (5’- AACCAGACAGCACCT-
ACTTCGACC-3’) and DNF (5’-ACCATGCTG TAC-
GTCGGTGACCCC-3’) were used for specific amplification
of TA-p73 and DN-p73 forms, respectively. For the detection
of p73 isoforms generated by dierential splicing between
exons 10 to 14, a forward primer from exon 10 (5’-
CGGCCATATT GGTGCCGCAGCCACTGGTG-3’) and
two dierent reverse primers were used. A reverse primer
from exon 13 (5’-GTTTGGCACCCCCAATCCTGT-3’) was
used for specific amplification of transcripts containing this
exon, i.e. p73a, p73e, and p73g (see Zaika et al., 1999 for
terminology). Another reverse primer, encompassing se-
quences from exon 12 followed by exon 14 (5’-AGGGCCCC-
CAGGTCCTGAGC-3’), was used for specific amplification
of p73b and p73f isoforms (Zaika et al., 1999) that contain
this particular sequence. p16INK4a and p14ARF RT–PCRs were
done using a specific forward primer for each transcript (5’-
CGGAGAGGGGGAGAACAGAC-3’ for p16INK4a and 5’-
TCACCTCTGGTGCCAAAGGG-3’ for p14ARF) and a
common reverse primer (5’-GGCAGTTGTGGCCCTG-
TAGG-3’). For the detection of cyclin E mRNA levels,
cyclin E-F (5’-TTGACCGGTATATGGCGACACAAG-3’)
and cyclin E-R (5’-ATGATACAAGGCCGAAGCAG-
CAAG-3’) primers were used. All RT –PCR reactions were
done using appropriate annealing and extension conditions
(additional information is available upon request). Equal
amount of RNA was used in cDNA synthesis and the
quality of cDNA was initially tested by GAPDH RT–PCR
amplification with primer pair F (5’-GGCTGAGAACGG-
GAAGCTTGTCAT-3’) and R (5’-CAGCCTTCTCCAT-
GGTGGTGAAGA-3’), using 1/40 vol-ume of cDNA
preparation. Further PCR studies were performed with
cDNA preparations yielding equal amounts of GAPDH
amplification products. Total PCR cycle numbers have been
defined following an initial study at 22, 26, 30 and 34
cycles, in order to remain in the logarithmic phase of
amplification. All RT –PCR results have been repeated
several times from dierent batches of RNA preparations
except primary tumours for which single RNA preparations
were used. The expression of TA-p73 isoform was
confirmed with an additional pair of primers, as described
by Fillippovich et al. (2001). The identity of dierent p73
isoforms (TA-p73, DN-p73, p73a, p73b, p73g, p73f) has
been confirmed by restriction enzyme mapping and
automated sequencing (PE, ABI PRISM 377 automated
sequencer) techniques.
Western blotting
The expression of retinoblastoma (pRb) and p53 proteins in
dierent cell lines was studied by Western blotting, using
anti-pRb IF8 (SC102, Santa Cruz Biotechnology) and anti-
p53 6B10 (Yolcu et al., 2001) monoclonal antibodies,
respectively, as described previously (Morel et al., 2000).
Equal protein loading was confirmed by blotting with control
antibody against cytokeratin 18 (JAR13 clone, gift from D
Bellet, Institut Gustave Roussy, France). p73 protein Western
Table 1 Comparative analysis of TA-p73 induction, E2F1 target gene activation and the retinoblastoma (RB1) pathway inactivation in HCC
cell lines
RB1 pathway genes EF21 target genes
Cell lines pRb p16INK4a TA-p73 p14ARF Cyclin E
Group I: Inactivated RB1 pathway
hep3B ND Positive Positive Positive Positive
Hep3B-TR ND Positive Positive Positive Positive
hep40 ND Positive Positive Positive Positive
FOCUS Traces Positive Positive Positive Positive
SNU-449 Positive ND Positive ND Positive
SNU-387 Positive ND Positive ND Positive
SK-hep1 Positive ND Positive ND Positive
PLC/PRF/5 Positive Traces Positive Positive Positive
SNU-475 Positive Traces Positive Positive Positive
SNU-398 Positive Traces Positive Positive Positive
SNU-423 Traces Traces Traces Positive Positive
Group II: Normal RB1 pathway
Mahlavu Positive Positive ND Positive Positive
SNU-182 Positive Positive Traces Positive Positive
HepG2 Positive Positive Positive Positive Positive
Huh-7 Positive Positive Positive Positive Positive
ND: not detected
Truncated p73 in liver and full-length p73 in hepatoma
AE Sayan et al
5116
Oncogene
blot assays were done with ER13 (Ab-1, Oncogene Research
Products, MA, USA) using the experimental procedure
described by Marin et al. (1998).
Abbreviations
HCC, hepatocellular carcinoma; RB1, retinoblastoma
gene; pRb, retinoblastoma protein.
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